Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Immune checkpoint inhibitors (ICIs) have exhibited promising efficacy in non-small cell lung cancer (NSCLC), but the response occurs in only a minority of patients. In clinic, biomarkers such as TMB (tumor mutation burden) and PD-L1 (programmed cell death 1 ligand 1) still have their limitations in...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Yanan, Liu, Xinyin, Wu, Yuemin, Liang, Xiao, Dai, Jiali, Zhang, Zhihong, Guo, Renhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960743/
https://www.ncbi.nlm.nih.gov/pubmed/35359393
http://dx.doi.org/10.3389/fonc.2022.798401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960743/
https://www.ncbi.nlm.nih.gov/pubmed/35359393
http://dx.doi.org/10.3389/fonc.2022.798401

Ejemplares similares